FD-895 is a spliceosome modulator derived from a polyketide natural product, targeting the SF3b subunit of the spliceosome. FD-895 possesses core biological activities for regulating RNA splicing (intron retention, alternative splicing) and inducing apoptosis of cancer cells. FD-895 can be used for the research of cancer, such as chronic lymphocytic leukemia (CLL).

Indolimine-214 is a metabolite of M. morganii Indolimine-214 increases the level of γH2AX in HeLa cells. Indolimine-214 can be used in the study of inflammatory bowel disease (IBD) and colorectal cancer (CRC).

S-cEt-U phosphoramidite is a modified phosphoramidite monomer that can be used for the oligonucleotide synthesis.

Morpholino G phosphoramidite (Compound 4b) is a nucleoside building block that is used for synthesis of morpholino oligonucleotides. Morpholino G phosphoramidite can be used for oligonucleotide therapies research.

Morpholino C phosphoramidite (Compound 4c) is a nucleoside building block that can be used for synthesis of morpholino oligonucleotides. Morpholino C phosphoramidite can be used for oligonucleotide therapies research.

5'-O-DMTr-Nap-dU-3'-CE Phosphoramidite is a phosphoramidite monomer used in nucleic acid synthesis, such as oligonucleotides.

5'(E)-VP-2'-OMe-Bz-C Phosphoramidite is a phosphoramidite monomer used in nucleic acid synthesis, such as oligonucleotides.

PolQi2 is a PolΘ inhibitor that specifically targets the N-terminal helicase domain of PolΘ, thereby suppressing alt-EJ (alternative end-joining) repair. This compound improves the accuracy and integration efficiency of gene editing across multiple loci and diverse cell lines. Additionally, it demonstrates synergistic effects with DNA-PK inhibitors in reducing Cas9-mediated off-target activity. Its application is suitable for gene editing studies.

Fraisinib is a specific and effective inhibitor of glycyl-tRNA synthetase 1 (GARS1), suppresses the synthesis of Ap4A by GARS1 and displays strong anti-tumoral potential.

RBI2 (Ribosome biogenesis inhibitor 2) is a small molecule inhibitor of ribosome biogenesis inhibitor, potently inhibits pre-rRNA levels in A375 with IC50 of 169 nM.

α,β-MTDP trisodium, a thymidylate analog, is a thymidine kinase inhibitor with a Ki of 23 µM.

Xanthosine-5'-Triphosphate (5'-XTP) trisodium, a nucleotide, is produced by deamination of purine bases. Xanthosine-5'-Triphosphate trisodium is a substrate of inosine triphosphate pyrophosphatase (ITPase).

VPC-80051 is an inhibitor of hnRNP A1 splicing activity. VPC-80051 directly interacts with hnRNP A1 RBD and reduces AR-V7 messenger levels in 22Rv1 CRPC cell line. VPC-80051 can be used in prostate cancer research.

Uridylyl-(3′→5′)-adenosine (UpA) is a dinucleotide, which is composed of a unrail base and an adenosine suger molecule through a 3'-5' phosphodiester bond. Uridylyl-(3′→5′)-adenosine participates in the biological processes, such as gene expression regulation, signal transduction, and protein synthesis.

Teloxantrone (CI-937; DUP 937) is a DNA synthesis inhibitor (IC50: 0.33 μM). Teloxantrone has antitumor activity and can be used in colorectal cancer research.

RNA recruiter 2 is a QSOX1 mRNA ligand. RNA recruiter 2 can serve as a ligand for target RNA (Ligands for Target RNA for RIBOTAC) for the development of RIBOTAC RNA degraders with antitumor activity. RNA recruiter 2 can be used for the synthesis of F1-RIBOTAC.

RNA binder 1 (Compound 4b) is a blood-brain permeable RNA binder. RNA binder 1 can selectively bind to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. RNA binder 1 significantly reduces the levels of toxic polypeptides poly(GA) and poly(GP) produced by the G4C2 repeat sequence in amyotrophic lateral sclerosis (ALS) patient-derived cells. RNA binder 1 has no significant effect on the antisense polypeptide poly(PR), showing selectivity for sense RNA. RNA binder 1 can be used in the study of ALS and frontotemporal dementia (FTD).

RECTAS-2.0 is a small molecule designed to correct RNA mis-splicing caused by the GLA c.639+919G>A mutation, used for the research of Fabry disease.

NSC 641396 is a ribonucleotide reductase (RNR) inhibitor with an IC50 value of 1.2 μM. NSC 641396 is also a protein arginine N-methyltransferase 9 (PRMT9) inhibitor. NSC 641396 has antitumor activity.

N-Palmitoyl-phenylalanine is an N-acyl amide that contains the long-chain saturated fatty acid Palmitic acid conjugated via an amide bond to the essential amino acid L-Phenylalanine. N-Palmitoyl-phenylalanine inhibits pre-mRNA splicing in HeLa cell nuclear lysates (IC50 ＞ 400 μM) but has no splicing activity in intact HeLa cells.

MRK-952 is a NUDIX hydrolase inhibitor. NUDIX enzymes are involved in cellular metabolism and homeostasis, as well as mRNA processing.

m7G(5')ppp(5')(2'OMeA)pU ammonium is a cap analog that can be used for in vitro transcription of mRNA.

m3227G(5)ppp(5')m6Am triammonium is the triammonium salt form of m3227G(5)ppp(5')m6Am.

m3227G(5)ppp(5')m6Am is a specific RNA molecule structure, which is composed of a 3227-methylguanine (m3227G) cap, a triphosphate group and a N6,2'-O-dimethyladenosine. m6Am is a reversible modification located on the first coding nucleotide near the 5' cap of mRNA, that can affect the stability of mRNA.

m3227G(5)ppp(5')Am triammonium is the triammonium salt form of m3227G(5)ppp(5')Am.

m3227G(5)ppp(5')Am is a specific mRNA molecule structure, which is composed of a 3227-methylguanine (m3227G) cap, a triphosphate group and a 2'-O-methyladenosine. Am is a reversible modification located on the first coding nucleotide near the 5' cap of mRNA, that can affect the stability of mRNA.

m3227G(5)ppp(5')A triammonium is the triammonium salt form of m3227G(5)ppp(5')A. OICR41114 can be used in anti-cancer research.

m3227G(5)ppp(5')A is a specific mRNA molecule structure, which is composed of a 3227-methylguanine (m3227G) cap, a triphosphate group and an adenosine. m3227G(5)ppp(5')A affects the stability and translation efficiency of mRNA.

Ledoxantrone (CI 958) is a DNA helicases inhibitor with an IC50 of 0.17 μM. Ledoxantrone can be used in the study of prostate cancer.

KWR137 is a WRN degrader, with an IC50 of 8 nM. KWR137 exhibits good anti-proliferative activity against MSI-H cells, with a GI50 of 509 nM in SW48 cells and a GI50 of 824 μM in HCT116 cells. It also demonstrates anti-tumor growth effects in xenograft mouse models. KWR137 can be used for cancer research.